Stock Events

Stock Events

Amarin

0

117

+€0.00+0% 00:00 Today

Statistics

Day High

-

Day Low

-

52W High

-

52W Low

-

Volume

-

Avg. Volume

-

Mkt Cap

0

P/E Ratio

-

Dividend Yield

-

Dividend

-

Financials

-18.47%Profit Margin

Unprofitable

2020

2021

2022

2023

2024

2025

184.81MRevenue

-34.14MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow EH3A.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

AstraZeneca competes with Amarin in the cardiovascular drug market, particularly with drugs aimed at reducing triglyceride levels and improving heart health.

Amgen offers a range of cardiovascular treatments that directly compete with Amarin's Vascepa, especially in the high triglyceride management space.

GlaxoSmithKline competes in the cardiovascular and metabolic disease areas, offering alternative treatments that could be used instead of Amarin's products.

Merck & Co. has a portfolio of cardiovascular drugs that can be seen as alternatives to Amarin's offerings, particularly in the lipid management space.

Pfizer has a broad range of cardiovascular drugs that compete with Amarin, including treatments for conditions that Vascepa is prescribed for.

Novartis competes with Amarin in the heart health market, with drugs that offer similar benefits to Vascepa in reducing cardiovascular risk.

AbbVie, through its broad portfolio in the pharmaceutical sector, competes in the cardiovascular space, offering treatments that could serve as alternatives to Amarin's products.

Sanofi has a presence in the cardiovascular disease treatment market, competing with Amarin with its range of heart health medications.

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, in partnership with Sanofi, develops drugs that compete in the same therapeutic areas as Amarin, including cardiovascular health.

About

Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally through wholesalers, selected regional wholesalers, and retail and mail order pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, EPA. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Show more...

CEO

Mr. Aaron D. Berg

Employees

80

Country

United Kingdom

ISIN

US0231112063

Listings

0 Comments

Share your thoughts

FAQ

What is Amarin stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Amarin stocks are traded under the ticker EH3A.MU.

What is Amarin revenue for the last year?▼

Amarin revenue for the last year amounts to 184.81M EUR.

What is Amarin net income for the last year?▼

EH3A.MU net income for the last year is -34.14M EUR.

How many employees does Amarin have?▼

As of July 24, 2026, the company has 80 employees.

In which sector is Amarin located?▼

Amarin operates in the Other sector.

When did Amarin complete a stock split?▼

The last stock split for Amarin was on April 11, 2025 with a ratio of 1:20.

Where is Amarin headquartered?▼

Amarin is headquartered in Dublin, United Kingdom.